Gene PlIRP1 and application thereof in preventing and treating litchi downy blight
Knocking out or replenishing the PlIRP1 gene of Phytie Cream lychee Cream lychee Cream lychee Cream lychee Cream lychee Cream disease prevention and control problem solving problems in the existing technology, significantly reducing the pathogenicity of Phytie Cream lychee Cream, providing New green prevention and control technologies and disease-resistant varieties have been selected.
Patent Information
- Application Number
- CN202411164193.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The prior art mainly relies on chemical pesticides when preventing and treating litchi cream. It has drug resistance risks and environmental pollution problems, and lacks effective disease-resistant litchi planting varieties.
By studying the pathogenic mechanism of Phytophthora lychee cream, we explored and used CRISPR/Cas9 gene editing technology to construct knockout and backfilling vectors of PlIRP1 protein, and knockout or backfilling Phytophthora lychee cream PlIRP1 gene was used to verify its pathogenic correlation.
The knockout mutant and recomplement strain of the PlIRP1 gene were successfully obtained, which significantly reduced or restored the pathogenicity of Phytophthora lychee cream, elucidated the important pathogenic correlation of PlIRP1 in Phytophthora lychee cream, and developed a new low-toxic bactericide. and disease-resistant varieties provide theoretical basis.
Smart Images

Figure CN119019519A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of green prevention and control of crop diseases, and particularly relates to a gene PlIRP1 and an application thereof in preventing and controlling litchi downy mildew. Background Art
[0002] Litchi downy mildew caused by Peronophythora litchii Chen ex Ko et al. is the most serious disease in litchi production. Due to the lack of effective disease-resistant litchi varieties, the current control of this disease is still mainly based on spraying chemical pesticides, which not only has a high risk of resistance, but also pollutes the environment. Therefore, it is of great significance to study the pathogenic mechanism of litchi downy mildew and then develop green control technology.
[0003] Studies have shown that the successful infection of litchi by litchi downy mildew mainly depends on a series of pathogenic factors. Therefore, exploring the important pathogenicity-related genes of litchi downy mildew and conducting functional studies can provide candidate drug targets for the prevention and control of litchi downy mildew and have great significance for the breeding of disease-resistant varieties. Summary of the invention
[0004] In order to overcome the shortcomings and deficiencies of existing technologies for controlling litchi downy mildew, the object of the present invention is to provide a litchi downy mildew pathogenicity-related protein PlIRP1 (Peronophythora litchiiinfection-related protein 1).
[0005] The present invention discloses a previously unknown protein PlIRP1 of litchi downy mildew and its encoding gene PlIRP1, the full length of the gene PlIRP 1 is shown in SEQ ID NO.1, there is no intron, and the 63 encoded amino acids are shown in SEQ ID NO.2. The present invention uses CRISPR / Cas9 gene editing technology to construct pBSSK::PlIRP1 and PYF2.3G-ribo-sgRNA::PlIRP1 knockout vectors, and knocks out the PlIRP1 gene by PEG-mediated protoplast transformation technology. Finally, knockout mutants T83 and T123 (named according to the sequence number of transformant verification) are obtained, and the two mutants have obvious defects in the growth and development process of litchi downy mildew. Similarly, CRISPR / Cas9 gene editing technology was used to construct pBSSK::NPTII and PYF2.3G-ribo-sgRNA1::NP TII and PYF2.3G-ribo-sgRNA2::NPTII in situ complementation vectors, and finally the complementation strain C140 was obtained. The results of pathogenicity assay showed that the knockout mutants T83 and T123 of the gene PlIRP1 significantly reduced the pathogenicity of litchi fruit (variety: Huaizhi), and the complementation strain of the gene PlIRP1 could restore the pathogenicity of C140 to the level of wild-type strains. The above experiments proved that the PlIRP1 gene of litchi downy mildew is an important pathogenicity-related gene of litchi downy mildew.
[0006] A litchi downy mildew pathogenicity-related protein PlIRP1, whose amino acid sequence is shown in SEQ ID NO.2, or a similar sequence obtained by replacing, inserting or deleting one or more amino acids in SEQ ID NO.2 and still having the same or similar function.
[0007] The above-mentioned biological material related to the litchi downy mildew pathogenicity-related protein PlIRP1 is any one or more combinations of the following biological materials:
[0008] 1) a nucleic acid molecule encoding the litchi downy mildew pathogenicity-related protein PlIRP1;
[0009] 2) an expression cassette containing the nucleic acid molecule described in 1);
[0010] 3) A recombinant vector containing the nucleic acid molecule described in 1), or a recombinant vector containing the expression cassette described in 2);
[0011] 4) a recombinant microorganism containing the nucleic acid molecule described in 1), or a recombinant microorganism containing the expression cassette described in 2), or a recombinant microorganism containing the recombinant vector described in 3);
[0012] 5) a nucleic acid molecule that inhibits or blocks the gene expression of the litchi downy mildew pathogenicity-related protein P1IRP1;
[0013] 6) A gene knockout vector for inhibiting or blocking the gene expression of the litchi downy mildew pathogenicity-related protein PlIRP1 prepared by using the nucleic acid molecule described in 5);
[0014] 7) A litchi downy mildew gene-deficient protein PlIRP1 associated with litchi downy mildew prepared by using the gene knockout vector described in 6).
[0015] Furthermore, the nucleic acid molecule in 1) is the gene sequence of the litchi downy mildew pathogenicity-related protein PlIRP1, as shown in SEQ ID NO: 1, or a similar sequence obtained by base insertion, deletion, or substitution as shown in SEQ ID NO.1 that still has the same or similar function.
[0016] Furthermore, the nucleic acid molecule in 5) is antisense RNA, siRNA, shRNA or sgRNA of the P1IRP1 gene.
[0017] Furthermore, the sgRNA is as follows:
[0018] sgRNA: 5'-CTAGCCAGCGCCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCGCGCTGCCAGTTCTTGGTCT-3'.
[0019] The application of the above-mentioned litchi downy mildew pathogenicity-related protein PlIRP1 or biomaterial is any one or more combinations of the following applications:
[0020] i) Application in regulating the pathogenicity of litchi downy mildew;
[0021] ii) Application in regulating the infection ability of litchi downy mildew;
[0022] iii) Application in regulating the oospore formation of Lychee Downy Phytophthora;
[0023] ⅳ) Application in the prevention and treatment of litchi frost blight;
[0024] ⅴ) Application as a target in the design and screening of drugs against litchi downy mildew.
[0025] A method for preventing and controlling litchi downy blight caused by litchi downy phyton, which is achieved by inhibiting or blocking the gene expression of the litchi downy phyton pathogenicity-related protein PlIRP1.
[0026] A drug screening model for resistance to litchi downy mildew, wherein the drug screening model is a litchi downy mildew gene-deficient protein PlIRP1 associated with litchi downy mildew.
[0027] The method for constructing the above-mentioned anti-litchi downy mildew drug screening model comprises the following steps:
[0028] (1) Design sgRNA according to the PlIRP1 gene sequence using the sgRNA website, connect the sgRNA with the pYF2.3G-Ribo-sgRNA vector to obtain the PlIRP1 gene knockout plasmid pYF2.3G-Ribo-sgRNA::PlIRP1;
[0029] Alternatively, left and right homology arm amplification primers are designed according to the PlIRP1 gene sequence, and the left and right homology arms are amplified using litchi downy mildew genomic DNA as a template; the obtained PlIRP1 gene left and right homology arms and NPTⅡ gene fragment are connected to the pBSSK vector to obtain the PlIRP1 gene knockout plasmid pBSSK::PlIRP1;
[0030] (2) The PlIRP1 gene knockout plasmids pYF2.3G-Ribo-sgRNA::PlIRP1 and pBSSK::PlIRP1 were introduced into the protoplasts of the wild-type strain of litchi downy mildew, and after screening and verification, the PlIRP1 gene knockout mutant was obtained, which is the litchi downy mildew drug screening model.
[0031] Furthermore, the sgRNA described in step (1) is as follows:
[0032] sgRNA: 5'-CTAGCCAGCGCCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCGCGCTGCCAGTTCTTGGTCT-3'.
[0033] Furthermore, the left and right homology arm amplification primers described in step (1) are as follows:
[0034] Left homology arm amplification primer:
[0035] PlIRP1-Left-F: 5'-AGAACTAGTGGATCCCCCGGGATCACCGACATGGAGGAGCAG-3';
[0036] PlIRP1-Left-R: 5'-ATCTTGTTCAATCATGTCTGTCGGATGTAGGAGACTGTG-3';
[0037] Right homology arm amplification primers:
[0038] PlIRP1-Right-F: 5'-GACGAGTTCTTCTGAACGCGCAGAAGGAGAGAAGAG-3';
[0039] PlIRP1-Right-R: 5'-ATCGAATTCCTGCAGCCCGGGCTATCAGGAGCAGGAGACAGCGT-3'.
[0040] Compared with the prior art, the present invention has the following advantages and effects:
[0041] The present invention proves through experiments that the upstream and downstream sequences of the gene PlIRP1 are amplified respectively, and then the NPTⅡ gene sequence is amplified, connected to the PBSSK vector, and knocked out by polyethylene glycol (PEG)-mediated protoplast transformation technology and CRISPR / Cas9 knockout strategy after homologous recombination. Because of the deletion of the gene PlIRP1, the mutant obtained has significantly reduced litchi downy mildew oospore production and pathogenicity compared with the wild type. The present invention confirms that the gene PlIRP1 is necessary for the formation and pathogenicity of litchi downy mildew oospores. Our research helps to further clarify the pathogenic molecular mechanism of litchi downy mildew, and provides a theoretical basis for discovering new drug action targets and designing new efficient, low-toxic and safe fungicides. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 This is a schematic diagram of the construction of homologous recombination of the litchi downy mildew PlIRP1 gene.
[0043] Figure 2 The figures are agarose gel electrophoresis diagrams of PCR verification of litchi downy mildew PlIRP1 gene knockout transformants and complemented transformants and quantitative PCR amplification result diagrams of litchi downy mildew PlIRP1 gene knockout transformants and complemented transformants; wherein, a is an electrophoresis diagram, and b is a quantitative PCR amplification result diagram; lane WT (Wild type): litchi downy mildew wild type; lane CK (Control): transformants in which the target gene is not knocked out after PEG transformation of an empty vector; lanes T83 and T123 respectively represent two knockout transformants of the gene PlIRP1; and lane C140 represents the complemented transformant of the gene PlIRP1.
[0044] Figure 3 Figure 2 is the result of pathogenicity analysis of litchi fruit inoculated with zoospores of gene PlIRP1 knockout mutants T83 and T123; wherein, a is the pathogenicity result of litchi fruit inoculated with zoospores of WT, CK, PlIRP1 knockout mutant and complemented strain 4 days ago, and the images are three representatives of each example; b is the lesion length measured 4 days after the fruit was inoculated with zoospores.
[0045] Figure 4The figure shows the results of pathogenicity analysis of litchi fruit inoculated with bacterial cakes of gene PlIRP1 knockout mutants T83 and T123; among them, a is the pathogenic result of WT, CK, PlIRP1 knockout mutant and complemented strain bacterial cake inoculated on litchi fruit 4 days ago, and the images are three representatives of each example; b is the lesion length measured 4 days after bacterial cake inoculation on leaves.
[0046] Figure 5 The figure is the analysis result of oospore yield of gene PlIRP1 knockout mutants T83 and T123; wherein, A is the oospore morphology diagram, the scale in the figure is 100 μm, and B is the statistical result of oospore yield. DETAILED DESCRIPTION
[0047] The present invention is further described in detail below in combination with actual practice and the accompanying drawings, but the implementation method of the present invention is not limited thereto.
[0048] If no specific experimental conditions are specified in the following embodiments, conventional experimental conditions or experimental conditions recommended by the reagent company are generally followed. The materials and reagents used, unless otherwise specified, are all reagents and materials obtained from commercial sources.
[0049] Example 1: Construction of P1IRP1 gene knockout vector
[0050] Test materials
[0051] Test strains, plants and vectors
[0052] The test strain is the wild type strain of litchi downy mildew (Peronophythora litchii, Wild Type, referred to as WT), which is a conventional downy mildew fungus that can be obtained through commercial channels or isolated from nature. The Eschrichia coli strain DH5α can be obtained through commercial channels. The plant material for inoculation is litchi (Huaizhi) fruit. The oomycete knockout and transformation vectors pYF2-PsNLS-hSpCas9, pYF2.3G-Ribo-sgRNA (disclosed in the literature "Yufeng, Fang, Linkai, et al. Efficient Genome Editing in the Oomycete Phytophthora sojae Using CRISPR / Cas9 [J]. Current Protocols in Microbiology, 2017"), and pBSSK (disclosed in the literature "ACRISPR / Cas9-mediated in situ complementation method for Phytophthora sojae mutants [J]. Molecular Plant Pathology, 2021, 22(3)”. The above vectors were kindly donated by the Laboratory of Oomycete and Fungal Molecular Biology, College of Plant Protection, Nanjing Agricultural University).
[0053] Main test culture medium
[0054] Carrot agar (CA) (1 L): 300 g carrot juice was squeezed, filtered through gauze, and sterilized at 121° C. for 20 min. 1.5% (W / V) agar powder was added to the solid culture medium.
[0055] LB medium (1 L): 5 g yeast extract, 10 g tryptone, 10 g sodium chloride (NaCl), sterilized at 121° C. for 20 min. Add 1.5% (W / V) agar powder to the solid medium.
[0056] Nutrition Pea Broth (NPB) (1L): 120g fresh peas were boiled in water for 20min and filtered. 5g sorbitol (D-Sorbitol), 5g mannitol (D-Mannitol), 5g glucose, 3g potassium nitrate (KNO3), 2g calcium carbonate (CaCO3), 2g yeast extract, 1g dipotassium hydrogen phosphate (K2HPO4), 1g potassium dihydrogen phosphate (KH2PO4), 0.5g magnesium sulfate (MgSO4), 0.1g calcium chloride (CaCl2), 2mL vitamin stock and 2ml trace elements were added to the filtrate, and ddH2O was added to make up to 1L, and sterilized at 121℃ for 20min. For solid culture medium, 1.5% (W / V) Difco Bacto Agar was added.
[0057] Pea mannitol medium (Pea / 0.5mol·L -1 Manitol, PM) (1L): 120g fresh peas, boiled in water for 20min, filtered. Add 91g D-Mannitol, 2g CaCO3 and 1.32g CaCl2 to the filtrate, add ddH2O to 1L, sterilize at 121℃ for 20min. For solid culture medium, add 1.5% (W / V) Difco Bacto Agar.
[0058] Petri medium (1L): 0.5g potassium dihydrogen phosphate, 0.25g magnesium sulfate heptahydrate (MgSO4·7H2O), 1g L-asparagine, 1mg vitamin B1, 0.5g yeast extract, 10mg β-sitosterol and 5g glucose, add ddH2O to 1L, sterilize at 121℃ for 20min. Add 1.5% agar powder to the solid medium.
[0059] Test methods
[0060] Construction of CRISPR / Cas9 technology-related vectors
[0061] (1) Construction of pYF2.3G-Ribo-sgRNA::PlIRP1
[0062] According to the website for designing sgRNA (http: / / grna.ctegd.uga.edu / ), the targeting RNA (sgRNA) on the PlIRP1 gene was selected and delivered to Bioengineering for synthesis. The sgRNA annealing system was prepared according to Table 1, and the metal bath was 37°C for 30 min.
[0063] PlIRP1-sgRNA-F: 5'-CTAGCCAGCGCCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCGCGCTGCCAGTTCTTGGTCT-3'
[0064] PlIRP1-sgRNA-R: 5'-AAACAGACCAAGAACTGGCAGCGCGACGAGCTTACTCGTTTCGTCCTCACGGACTCATCAGGCGCTGG-3'.
[0065] (2) Construction of PYF2.3G-ribo-sgRNA1::NPTII and PYF2.3G-ribo-sgRNA2::NPTII
[0066] According to the sgRNA design website (http: / / grna.ctegd.uga.edu / ), the targeting RNA (sgRNA, including sgRNA1 and sgRNA2) on the NPTII gene was selected and delivered to Bioengineering for synthesis. The sgRNA annealing system was prepared according to Table 1, and the metal bath was 37°C for 30 min.
[0067] NPTII-sgRNA1-F: 5'-CTAGCAAGCAGCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCCTGCTTGCCGAATATCATGG-3'
[0068] NPTII-sgRNA1-R:5'-AAACCCATGATATTCGGCAAGCAGGACGAGCTTACTCGTTTCGTCCTCACGGACTCATCAGCTGCTTG-3'
[0069] NPTII-sgRNA2-F: 5'-CTAGCCAGAGCCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCGCTCTGATGCCGCCGTGTTC-3'
[0070] NPTII-sgRNA2-R: 5'-AAACGAACACGGCGGCATCAGAGCGACGAGCTTACTCGTTTCGTCCTCACGGACTCATCAGGCTCTGG-3'.
[0071] Table 1 sgRNA synthesis system (Takara)
[0072]
[0073] Then, 4 μL of 0.5 mol·L -1 NaCl, mix well and boil in a boiling water bath for 2 minutes, cool at room temperature for 3-4 hours, and the DNA fragments anneal to form double strands.
[0074] The targeting RNA (sgRNA) on the PlIRP1 and NPTII genes annealed to form a double strand, and was ligated with the pYF2.3G-Ribo-sgRNA vector (enzyme digestion system is shown in Table 2) after restriction digestion using T4-DNA ligase. The ligation system is shown in Table 3. The reaction conditions are 16°C, 4h, cooled on ice, and then transformed into Escherichia coli.
[0075] Table 2 pYF2.3G-Ribo-sgRNA vector double enzyme digestion system (50 μL) (NEB)
[0076]
[0077] Table 3 pYF2.3G-Ribo-sgRNA vector and double-stranded sgRNA ligation reaction system (10 μL) (NEB)
[0078]
[0079]
[0080] (3) Construction of pBSSK::PlIRP1 vector
[0081] Based on the approximately 1 kb sequence upstream and downstream of the PlIRP1 gene and the NPTⅡ gene, amplification primers (PlIRP1-Left-F, PlIRP1-Left-R, PlIRP1-Right-F, PlIRP1-Right-R, NPTⅡ-F, NPTⅡ-R) were designed. PlIRP1-Left-F: 5'-AGAACTAGTGGATCCCCCGGGATCACCGACATGGAGGAGCAG-3'
[0082] PlIRP1-Left-R: 5'-ATCTTGTTCAATCATGTCTGTCGGATGTAGGAGACTGTG-3'
[0083] PlIRP1-Right-F: 5'-GACGAGTTCTTCTGAACGCGCAGAAGGAGAGAAGAG-3'
[0084] PlIRP1-Right-R: 5'-ATCGAATTCCTGCAGCCCGGGCTATCAGGAGCAGGAGACAGCGT-3'
[0085] NPTⅡ-F:5'-ATGATTGAACAAGATGGATTGCAC-3'
[0086] NPTⅡ-R: 5'-TCAGAAGAACTCGTCAAGAAGGC-3'.
[0087] (4) Construction of pBSSK::NPTⅡ vector
[0088] Based on the sequences of about 1 kb upstream and downstream of the PIIRP1 gene, the amplification primers (PIIRP1-Left-F and PIIRP1-Right-R) were used to amplify the sequences of about 1 kb upstream and downstream of the PIIRP1 gene.
[0089] PlIRP1-Left-F: 5'-AGAACTAGTGGATCCCCCGGGATCACCGACATGGAGGAGCAG-3'
[0090] PlIRP1-Right-R: 5'-ATCGAATTCCTGCAGCCCGGGCTATCAGGAGCAGGAGACAGCGT-3'.
[0091] Phanta Max Super-Fidelity DNA Polymerase (Nanjing Novozyme) was used for PCR amplification. The left and right homologous arm sequences were amplified using the genomic DNA of litchi downy mildew as a template, and the NPTⅡ gene sequence was amplified from the NPTⅡ resistance vector (reference "Fang Y, Tyler BM. Efficient disruption and replacement of an effector gene in the oomycete Phytophthora sojae using CRISPR / Cas9 [J]. Molecular Plant Pathology, 2016: 127-139."). At the same time, the genomic DNA of litchi downy mildew was directly used as a template to amplify the PlIRP1 gene and its upstream and downstream sequences of about 1 kb each. The specific PCR amplification system is shown in Table 4 below:
[0092] Table 4 Phanta Max high-fidelity enzyme PCR amplification system (50 μL)
[0093]
[0094]
[0095] The amplification procedure was as follows: pre-denaturation at 95°C for 3 min, denaturation at 95°C for 15 s, annealing at 56-72°C for 15 s, extension at 72°C for 30 s / kb, 34 cycles, and finally extension for 5 min. The target band was detected by electrophoresis and then recovered using the agarose gel purification recovery kit of OMEGA. For specific steps, refer to the instructions of the kit. The concentration of the obtained product PlIRP1 gene left and right homologous arm sequences and NPTⅡ gene was detected and then connected with the linearized pBSSK vector (the circular pBSSK vector was digested by SmaⅠ restriction endonuclease NEB, the reaction conditions were 25°C, 2h. The product after digestion was purified and recovered using the PCR purification kit of OMEGA). The connection system is shown in Table 5 to obtain pBSSK::PlIRP1. After amplifying the PlIRP1 gene and its upstream and downstream sequences of approximately 1 kb each, this gene sequence can be connected to the linearized pBSSK vector. The restriction digestion conditions and connection system of the pBSSK vector are the same as those of the above-mentioned pBSSK::PlIRP1 vector, and finally pBSSK::NPTII is obtained.
[0096] Table 5 pBSSK::PlIRP1 and pBSSK::NPTII vector ligation reaction system (10 μL)
[0097]
[0098] The constructed pYF2.3G-Ribo-sgRNA::PlIRP1, PYF2.3G-ribo-sgRNA1::NPTII, PYF2.3G-ribo-sgRNA2::NPTII, pBSSK::PlIRP1, pBSSK::NPTII and pYF2-PsNLS-hSpCas9 were transformed into Escherichia coli.
[0099] (5) E. coli transformation and verification
[0100] 100 μL of E. coli competent cells DH5α were frozen and thawed on ice, 10 μL of the ligation product was added, and the mixture was mixed by tapping with fingertips, and the mixture was placed on ice for 30 min. Heat shock was performed in a 42°C water bath for 90 s, and then quickly placed on ice for 2 min. 650 μL of LB liquid culture medium was added to the tube and cultured at 37°C and 180 rpm for 1 h. During this process, E. coli resumed its growth state and expressed the antibiotic resistance gene encoded by the plasmid. The above bacterial solution was centrifuged at 4000 rpm for 4 min, the supernatant was aspirated, and the remaining 100 μL of LB culture medium was used to suspend the bacteria and spread on a plate containing a final concentration of 100 μg mL -1 The Amp was cultured on LB solid screening plates at 37°C for 12 to 16 hours.
[0101] Using a single colony of Escherichia coli as a template, the verification primers for the pYF2.3G-Ribo-sgRNA vector were M13F and RPL41_Pseq_F; the verification primers for the pBSSK vector were M13F and M13R; among them, M13F and M13R were universal primers, and the sequence of primer RPL41_Pseq_F was as follows: RPL41_Pseq_F: 5'-CAAGCCTCACTTTCTGCTGACTG-3'.
[0102] Green Taq Mix (Nanjing Novozyme) was used for colony PCR verification, and the system is as shown in Table 6:
[0103] Table 6 Colony PCR reaction system (20 μL)
[0104]
[0105] The PCR amplification program was as follows: pre-denaturation at 94°C for 5 min, denaturation at 94°C for 30 s, annealing at 60°C for 30 s, extension at 72°C for 30 s / kb, 30 cycles, and extension for 7 min. The amplified products were detected by gel electrophoresis, and two colonies with amplified bands that matched the target fragment size were selected and stained with 100 μg mL -1 Amp was cultured in LB liquid medium and sent for sequencing.
[0106] (6) Large-scale extraction of plasmid DNA
[0107] Select a single colony of E. coli containing the target plasmid and shake it. Add the single colony to a solution containing 100 μg mL -1 The culture medium was added to 200 mL of LB liquid medium containing Amp and cultured at 37°C, 200 rpm for 12 h. The culture medium was then added to 200 mL of LB liquid medium containing Amp and cultured at 37°C, 200 rpm for 14 h.
[0108] The plasmids required for PEG-mediated transformation were extracted using TIANGEN's EndoFree Maxi Plasmid Kit. Three plasmids (pYF2-PsNLS-hSpCas9, pYF2.3G-Ribo-sgRNA::PlIRP1, and pBSSK::PlIRP1) were required for PlIRP1 gene knockout, while four plasmids (pYF2-PsNLS-hSpCas9, pBSSK::NPTII, pYF2.3G-Ribo-sgRNA1::NPTII, and pYF2.3G-Ribo-sgRNA2::NPTII) were required for PlIRP1 gene complementation.
[0109] Example 2: Preparation of protoplasts of Peronophytum litchii and PEG-mediated transformation
[0110] Preparation of enzymatic solution: weigh 0.15g Lysing Enzymes (SIGMA) and 0.06g Cellulase (SIGMA) in a sterile beaker, add 10mL 0.8mol·L -1 Mannitol, 8 mL sterile ddH2O, 800 μL 0.5 mol·L -1 KCl, 800 μL 0.5 mol·L -1 MES-KOH and 400 μL 0.5 mol·L -1 After CaCl2 is fully dissolved, transfer to a 50 mL centrifuge tube for later use;
[0111] Preparation of W5solution: weigh 7.8 g Glucose, 4.6 g CaCl2, 2.25 g NaCl, 0.093 g KCl, add ddH2O to make up to 250 mL, and set aside;
[0112] Preparation of MMg solution: weigh 18.22 g of mannitol, 0.76 g of MgCl2·6H2O, and 2 mL of MES Buffer, add water to make up to 250 mL, and set aside;
[0113] The wild-type strain of Peronophytum litchii WT was activated on nutrient pea solid plate medium (NPB solid medium). Take the mycelium block and put it into a conical flask, add 50mL NPB liquid medium for cultivation, and culture three bottles in total. Culture at 25℃ in the dark for 3d, and shake once every 12h. Filter the gauze, collect the mycelium, squeeze it gently with tweezers, and add it to a 50mL centrifuge tube containing enzymatic solution. After gently mixing, enzymolysis is carried out at 25℃, 40rpm for 40-45min. After the mycelium is enzymatically hydrolyzed, quickly filter the mycelium with a 50mL beaker wrapped with three layers of Miracloth filter cloth, and transfer the filtrate to a 50mL round-bottom centrifuge tube, centrifuge at 4℃, 1500rpm for 3min. Discard the supernatant, add 10mL W5solution to resuspend the protoplasts, add 25mL W5solution, gently mix upside down, and centrifuge at 4℃, 1500rpm for 4min. The supernatant was discarded, and 7 mL of W5 solution was added to resuspend the protoplasts, and the mixture was placed on ice for 30 min. Then, the mixture was centrifuged at 1500 rpm for 4 min at 4°C, the supernatant was discarded, and 6 mL of MMg solution was added to resuspend the protoplasts, and the mixture was placed in the greenhouse for 10 min. Take 6 sterilized 50mL centrifuge tubes and place them on ice. When knocking out the PlIRP1 gene, add 3 plasmids to each centrifuge tube: pYF2-PsNLS-hSpCas9, pY F2.3G-Ribo-sgRNA::PlIRP1, and pBSSK::PlIRP1, 30μg each; when complementing the PlIRP1 gene, add 4 plasmids to each centrifuge tube: pYF2-PsNLS-hSpCas9, pBSSK::NPTII, pYF2.3G-Ribo-sgRNA1::NP TII, and pYF2.3G-Ribo-sgRNA2::NPTII, also 30μg each, to obtain MMg solution containing protoplasts.
[0114] Add 1 mL of MMg solution containing protoplasts to each 50 mL centrifuge tube, shake gently to mix, and place on ice for 10 min. Add 580 μL of 40% polyethylene glycol (PEG) solution to each centrifuge tube along the tube wall, and add three times in succession. During this process, slowly rotate the centrifuge tube to mix the PEG and protoplasts, and place on ice for 20 min. Add 100 mg mL PEG to pea mannitol culture medium (PM) at a dilution of 1000:1. -1Amp PM was prepared from ampicillin. Add 2 mL of Amp PM to a centrifuge tube, gently turn it upside down, and place it on ice for 2 min; continue to add 8 mL of Amp PM to the centrifuge tube, gently turn it upside down, and place it on ice for 2 min; finally, add 10 mL of Amp PM to each centrifuge tube in turn, gently turn it upside down, and place it at an angle. Incubate in the dark at 25°C for 14 to 16 hours to allow the protoplasts to regenerate. After overnight incubation, observe the regeneration of the protoplasts under a microscope, and then centrifuge at 2000 rpm for 5 min. Discard the supernatant from each centrifuge tube until 5 mL of liquid culture medium remains, suspend the precipitate, and add 30 mL of 30 μg·mL -1 Antibiotic-free pea mannitol solid medium. When knocking out the PlIRP1 gene, use Geneticin G418; when complementing the PlIRP1 gene, use hygromycin. Add the corresponding antibiotics, mix thoroughly by inversion, and pour into two 9 cm sterile culture dishes. Culture at 25°C in the dark for 2 to 3 days. Pick a single colony and number it for identification.
[0115] Example 3: Validation and determination
[0116] (1) PCR agarose gel electrophoresis verification of PlIRP1 gene knockout and complementation transformants
[0117] The genomic DNA of the wild type WT and transformants of Litchi Downy Phytophthora was extracted by CTAB method, and the genomic DNA was used as a template to design primers PlIRP1-OUT-F and PlIRP1-OUT-R outside the left and right homologous arm fragments of the genome for conventional PCR amplification. The band size was detected by gel electrophoresis to verify whether PlIRP1 was successfully knocked out and sent for sequencing detection.
[0118] PlIRP1-OUT-F:5'-GTCAGAAGGGGTATATGGGGAAAC-3'
[0119] PlIRP1-OUT-R: 5'-GACCTCCTGTATTTGGACACGAAC-3'.
[0120] The sequencing results proved that the PEG transformation knockout and complementation were successful, and two PlIRP1 gene knockout transformants and complementation transformants were obtained. They were numbered from T1 according to the verification order. The two successful knockout mutants were named T83 and T123, and the complementation transformant was named C140.
[0121] (2) Fluorescence quantitative analysis verification of PlIRP1 gene knockout and complementation transformants
[0122] The mycelia of wild-type WT and transformants of litchi downy mildew were used for RNA extraction using the All-In-One DNA / RNA Mini-Preps Kit of BBI, and the genomic DNA was removed and reverse transcription cDNA was synthesized using the FastKing cDNA first-strand synthesis kit of Tiangen. The quantitative primers PlActin-F and PlActin-R were designed using the PlActin gene as the internal reference gene, and the quantitative primers PlIRP1-qPCR-F and PlIRP1-qPCR-R were designed using the CDS sequence of the PlIRP1 gene as the target gene. Real-time fluorescence quantitative PCR was performed using the SYBR Premix Ex Taq TM kit (TAKARA), and the expression of the PlIRP1 gene was analyzed to verify whether the PlIRP1 gene was successfully knocked out and complemented.
[0123] PlActin-F:5'-TCACGCTATTGTTCGTCTGG-3'
[0124] PlActin-R: 5'-TCATCTCCTGGTCGAAGTCC-3'
[0125] PlIRP1-qPCR-F: 5'-AAGTACACGTGGTCCCG-3'
[0126] PlIRP1-qPCR-R: 5'-GCTCGAGTAAAGCGCCAAC-3'.
[0127] (3) Determination of pathogenicity of knockout mutants
[0128] The wild-type WT strain of Peronophytum litchii, the transformant CK that grew in the medium containing G418 antibiotics but failed to be knocked out, and the mutants T83, T123 and complemented transformant C140 that successfully knocked out the PlIRP1 gene were transferred twice on CA plates without antibiotics, and the 9mm diameter mycelial blocks of WT, CK, T83, T123 and C140 with the same bacterial age were punched out and inoculated in the center of a 15mL equal amount of carrot medium plate (diameter = 9cm). After culturing them in the dark at 25℃ for 5d, the 9mm diameter mycelial blocks of WT, CK, T83, T123 and C140 with the same bacterial age were punched out, and 5 of each group were placed in 2.5mL ddH2O and shaken with a vortex oscillator for 1min to make the sporangia fully fall off from the sporangiophore to obtain a sporangial suspension. The sporangial suspension was placed in a 16℃ incubator to allow the zoospores to be released, and the zoospores were counted and diluted to 10 zoospores / μL under a microscope. Litchi (Huaizhi) fruits were washed with ddH2O and dried on a clean bench. Each litchi fruit was inoculated with 60 μL of zoospore suspension, and the number of fruit inoculation was 10. The fruit was cultured at 25°C to keep moist. After 4 days, photos were taken and the diameter of the lesions was measured. Duncan's multiple range test in SPSS software was used for significant difference analysis.
[0129] Take the WT, CK, T83, T123 and C140 mycelium blocks with the same bacterial age and diameter of 9 mm obtained by the transfer culture in the above steps, inoculate them on the fruit side of the Huaizhi variety litchi fruit, and inoculate 10 fruits with each strain repeatedly. Place them at 25℃ to keep moist, take pictures after 4 days and measure the diameter of the lesions.
[0130] (4) Determination of oospore production of knockout mutants
[0131] At the edge of the colonies of WT, CK, T83, T123 and C140 after two transfer cultures, bacterial discs of the same size (d = 9 mm) were removed with a sterile cork puncher and transferred to carrot culture medium covered with a layer of Hybond N + membrane. After dark culture at 25 ° C for 10 days, the filter membrane was removed, and 4 bacterial discs were randomly punched with a cork punch near the inoculation point, placed in 4 mL ddH2O for homogenization, and 1 μL was aspirated on a slide to count the number of oospores of each strain.
[0132] Example 4: Results and Analysis
[0133] (1) Construction of the recombinant fragment of the PlIRP1 gene of Peronophytum litchii
[0134] The PCR technology was used to clone the homology arm Left and Right sequence fragments of the PlIRP1 gene and the NP TⅡ gene sequence fragment, and the multiple fragments were connected to the linearized PBSSK vector to successfully obtain the pBSSK::PlIRP1 vector; the double-stranded synthesis obtained sgRNA, which was connected to the linearized pYF2.3G-Ribo-sgRNA vector to successfully obtain the pYF2.3G-Ribo-sgRNA::PlIRP1 vector. The knockout diagram is shown in the figure. Figure 1 .
[0135] (2) Screening of knockout mutants of the litchi downy mildew gene PlIRP1
[0136] The genomic DNA of the wild type WT and transformants of litchi downy mildew was extracted by CTAB method. The genomic DNA was used as a template to design primers P1IRP1-OUT-F and P1IRP1-OUT-R outside the left and right homologous arm fragments of the genome for conventional PCR amplification. The band size was detected by gel electrophoresis ( Figure 2 ) proved that PEG conversion knockout was successful.
[0137] The expression of the knockout transformant PlIRP1 gene was analyzed by real-time fluorescence quantitative PCR using the real-time fluorescence quantitative PCR primers PlIRP1-qPCR-F and PlIRP1-qPCR-R of the gene PlIRP1 and the real-time fluorescence quantitative PCR primers PlActin-F and PlActin-R of the PlActin gene as the internal reference gene. The results showed that both T83 and T123 transformants could not express the PlIRP1 gene, indicating that T83 and T123 were knockout transformants of the gene PlIRP1 ( Figure 2 ), and sequencing results confirmed that it had indeed been knocked out.
[0138] (3) Pathogenicity analysis of PlIRP1 knockout mutants
[0139] Compared with the wild-type WT, CK and complemented strain C140 of litchi downy mildew, the knockout mutants T83 and T123 showed significantly reduced lesion diameters after inoculation with the same concentration of zoospore suspension and bacterial cakes with the same colony diameter, proving that the deletion of the gene PlIRP1 significantly reduced the pathogenicity of litchi downy mildew ( Figure 3 , Figure 4 ).
[0140] (4) Effect of the PlIRP1 knockout mutant on oospore production
[0141] Under the same treatment conditions, oospore suspensions of wild-type WT, CK, complemented strain C140, and knockout mutants T83 and T123 were prepared. Compared with WT, CK, and complemented strain C140, the oospore production of knockout mutants T83 and T123 decreased, indicating that knockout gene PlIRP1 would affect the production of oospores of litchi Downy Phytophthora ( Figure 5 ).
[0142] Therefore, the gene provided by the present invention can be used for plant disease prevention and control, especially litchi downy blight caused by litchi downy blight. In addition, the gene provided by the present invention can be used as a drug target for plant disease prevention and control. Those skilled in the art can develop drugs for preventing and controlling plant diseases, especially litchi downy blight, according to the guidance and inspiration of this specification.
[0143] The above examples are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above examples. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principles of the present invention shall be equivalent alternatives and shall be included in the protection scope of the present invention.
Claims
1. A litchi downy mildew pathogenicity-related protein PlIRP1, characterized in that: Its amino acid sequence is shown in SEQ ID NO.2, or is a similar sequence obtained by replacing, inserting or deleting one or more amino acids in SEQ ID NO.2 and still having the same or similar function.
2. The biomaterial related to the litchi downy mildew pathogenicity-related protein PlIRP1 according to claim 1, characterized in that: Any one or more combinations of the following biological materials: 1) a nucleic acid molecule encoding the litchi downy mildew pathogenicity-related protein PlIRP1; 2) an expression cassette containing the nucleic acid molecule described in 1); 3) A recombinant vector containing the nucleic acid molecule described in 1), or a recombinant vector containing the expression cassette described in 2); 4) a recombinant microorganism containing the nucleic acid molecule described in 1), or a recombinant microorganism containing the expression cassette described in 2), or a recombinant microorganism containing the recombinant vector described in 3); 5) a nucleic acid molecule that inhibits or blocks the gene expression of the litchi downy mildew pathogenicity-related protein P1IRP1; 6) A gene knockout vector for inhibiting or blocking the gene expression of the litchi downy mildew pathogenicity-related protein PlIRP1 prepared by using the nucleic acid molecule described in 5); 7) A litchi downy mildew gene-deficient protein PlIRP1 associated with litchi downy mildew prepared by using the gene knockout vector described in 6).
3. The biomaterial according to claim 2, characterized in that: 1) The nucleic acid molecule is the gene sequence of the litchi downy mildew pathogenicity-related protein PlIRP1, as shown in SEQ ID NO: 1, or a similar sequence obtained by base insertion, deletion, or substitution as shown in SEQ ID NO. 1 that still has the same or similar function; 5) The nucleic acid molecule is antisense RNA, siRNA, shRNA or sgRNA of the P1IRP1 gene.
4. The biomaterial according to claim 3, characterized in that: The sgRNA is as follows: sgRNA: 5'-CTAGCCAGCGCCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCGCGCTGCCAGTTCTTGGTCT-3'.
5. Use of the litchi downy mildew pathogenicity-related protein PlIRP1 as claimed in claim 1 or the biomaterial as claimed in any one of claims 2 to 3, characterized in that: Any one or more combinations of the following applications: i) Application in regulating the pathogenicity of litchi downy mildew; ii) Application in regulating the infection ability of litchi downy mildew; iii) Application in regulating the oospore formation of Lychee Downy Phytophthora; ⅳ) Application in the prevention and treatment of litchi frost blight; ⅴ) Application as a target in the design and screening of drugs against litchi downy mildew.
6. A method for preventing and controlling litchi downy blight caused by litchi downy blight, characterized in that: This is achieved by inhibiting or blocking the gene expression of the litchi downy mildew pathogenicity-related protein PlIRP1 described in claim 1.
7. A drug screening model for resistance to litchi downy mildew, characterized in that: The drug screening model is a litchi downy mildew gene-deficient protein PlIRP1 associated with litchi downy mildew described in claim 1.
8. The method for constructing a drug screening model against litchi downy mildew as claimed in claim 7, characterized in that: The steps include: (1) Design sgRNA according to the PlIRP1 gene sequence using the sgRNA website, connect the sgRNA with the pYF2.3G-Ribo-sgRNA vector to obtain the PlIRP1 gene knockout plasmid pYF2.3G-Ribo-sgRNA::PlIRP1; Alternatively, according to the PlIRP1 gene sequence, left and right homologous arm amplification primers are designed, and the left and right homologous arms are amplified using litchi downy mildew genomic DNA as a template, and the obtained PlIRP1 gene left and right homologous arms and NPTⅡ gene fragments are connected to the pBSSK vector to obtain the PlIRP1 gene knockout plasmid pBSSK::PlIRP1; (2) The PlIRP1 gene knockout plasmids pYF2.3G-Ribo-sgRNA::PlIRP1 and pBSSK::PlIRP1 were introduced into the protoplasts of the wild-type strain of litchi downy mildew, and after screening and verification, the PlIRP1 gene knockout mutant was obtained, which is the litchi downy mildew drug screening model.
9. The method for constructing a screening model for drugs against litchi downy mildew according to claim 8, characterized in that: The sgRNA described in step (1) is as follows: sgRNA: 5'-CTAGCCAGCGCCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCGCGCTGCCAGTTCTTGGTCT-3'.
10. The method for constructing a screening model for drugs against litchi downy mildew according to claim 8, characterized in that: The left and right homology arm amplification primers described in step (1) are as follows: Left homology arm amplification primer: PlIRP1-Left-F: 5'-AGAACTAGTGGATCCCCCGGGATCACCGACATGGAGGAGCAG-3'; PlIRP1-Left-R: 5'-ATCTTGTTCAATCATGTCTGTCGGATGTAGGAGACTGTG-3'; Right homology arm amplification primers: PlIRP1-Right-F: 5'-GACGAGTTCTTCTGAACGCGCAGAAGGAGAGAAGAG-3'; PlIRP1-Right-R: 5'-ATCGAATTCCTGCAGCCCGGGCTATCAGGAGCAGGAGACAGCGT-3'.
Citation Information
Patent Citations
Application of gene PlRACK1 in regulation and control of growth, oxidation resistance and pathogenicity of peronophythora litchii
CN114774457A
Application of gene PlRAB6 in regulation and control of pathogenicity of peronophythora litchii
CN114891814A
Gene PlMYB1R and application thereof in preventing and treating peronophythora litchii
CN114989273A
Use of nat1 gene as screening marker in genetic transformation of oomycetes
WO2022166433A1
